Pentax rejects Ambu's claims of head start

The pandemic has created a market frenzy for single-use bronchoscopes. Pentax Medical denies that Ambu has a head start over its closest international rivals.
Photo: Pentax / PR
Photo: Pentax / PR
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN

According to Pentax Medical, the pandemic has accelerated the demand for medical products that can be used without the risk of infection, increasing the competition on the global market for single-use endoscopes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading